Companies Cryptocurrencies
Eloxx Pharmaceuticals Inc
Eloxx Pharmaceuticals Inc
Exchange: NasdaqGM
IPO Date: 23/11/2012
CEO: Mr. Robert Ward
Biotechnology Healthcare 🔗
  • ELOX
  • 1.5
  • 129304200
    market cap
  • 0.01999998
If you bought

shares of Eloxx Pharmaceuticals Inc (ELOX) on
You would have made
Old Price $12 Current Price $12

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug candidates. The company is headquartered in Waltham, Massachusetts and currently employs 29 full-time employees. The firm is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). The company is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Address: 950 Winter St Waltham MASSACHUSETTS 02451

Stay updated.